Rs 1,102.90 apiece. The company reported that its consolidated net profit fell 11.3% on the year to Rs 346 crore in the ...

The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) yesterday approved Tepezza (teprotumumab (Tepezza). This ...

IOL leverages Pure Refractive Optics Technology, featuring a continuous refractive surface across the optical diameter.

AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their HER2-directed antibody drug ...